Breadcrumb

Photograph of Charalampos Floudas

Charalampos “Harris” S. Floudas, MD, DMSc, MS

  • Center for Cancer Research
  • National Cancer Institute
Assistant Research Physician
Center for Immuno-Oncology
Head of HNC Therapy, Immunotherapy Section

RESEARCH SUMMARY

Dr Floudas is a Board Certified Medical Oncologist specializing in Head and Neck Cancer (HNC). He is clinically active in drug development for HNC, designing and conducting bench-to-bedside early-phase investigator-initiated clinical trials of immunotherapy and complex biologics. 

Current clinical trials are addressing primarily mucosal Squamous Cell Cancer of the Head and Neck (HNSCC/SCCHN) in the recurrent/metastatic but also in the curative setting, as well as rare cancers of the Head and Neck, such as Olfactory Neuroblastoma (esthesioneuroblastoma) and Sinonasal Undifferentiated Carcinoma (SNUC). 

His translational research interests include machine learning (AI?ML) analysis of multimodal omics for biomarker discovery and to resolve questions in tumor immunology, such as the complex topography and interactions shaping the tumor microenvironment.

Dr Floudas is also exploring the applications of LLMs in Oncology, particularly looking at increasing the efficiency of clinical trial workflows, including patient-clinical trial matching. 

Areas of Expertise

Cancer Immunology and Immunotherapy
The Tumor Microenvironment
Medical Oncology
Clinical Computational Oncology
Artificial Intelligence/Machine Learning

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Publications

Selected Key Publications

Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial

Floudas CS, Goswami M, Donahue RN, Pastor DM, Redman JM, Brownell I, Turkbey EB, Cordes LM, Steinberg SM, Manu M, Francis DC, Lamping E, Marté JL, Kackley M, Krauss E, Manukyan M, Jochems C, Schlom J, Gulley JL, Strauss J.
JAMA Onc. 2025.
Full-Text Article
[ Journal Article ]

Matching patients to clinical trials with large language models

Qiao Jin, Zifeng Wang, Charalampos S Floudas, Fangyuan Chen, Changlin Gong, Dara Bracken-Clarke, Elisabetta Xue, Yifan Yang, Jimeng Sun, Zhiyong Lu
Nature Communications. 15(1): 2024.
Full-Text Article
[ Journal Article ]

Leveraging mRNA technology for antigen based immuno-oncology therapies

Charalampos S Floudas, Siranush Sarkizova, Michele Ceccarelli, Wei Zheng
Journal for ImmunoTherapy of Cancer (JITC). 13: 2025.
Full-Text Article
[ Journal Article ]

Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies

Elisabetta Xue, Dara Bracken-Clarke, Harris Krause, Tolulope Adeyelu, Mark G Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P Soares, Emil Lou, Minh Phan, Rusha Patel, Ari M Vanderwalde, Andrew Elliott, Conor E Steuer, Nabil F Saba, Daniel J Lubin, Nyall R London Jr, James L Gulley, Charalampos S Floudas
Cancers (Basel). 16: 2024.
Full-Text Article
[ Journal Article ]

Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study

Giovanni Maria Iannantuono, Dara Bracken-Clarke, Fatima Karzai, Hyoyoung Choo-Wosoba, James L Gulley, Charalampos S Floudas
The Oncologist. 2024.
Full-Text Article
[ Journal Article ]